Transfection

SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer

Retrieved on: 
Thursday, July 13, 2023
Therapy, A.I, Intelligence, Statistics, RNA, Transfection, Hydrolysis, Bayesian network, COVID-19, Machine learning, Algorithm, Drug discovery, Deep learning, Artificial intelligence, Knowledge, Silicon, Particle size, Pharmaceutical industry, Video game, Fine chemical

GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I.

Key Points: 
  • GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I.
  • As a member of the Company’s leadership team, Mr. Tzagkarakis will be responsible for designing a neurosymbolic engine to accelerate the development of next-generation Bio-Courier formulations.
  • Mr. Tzagkarakis brings over 15 years’ senior leadership and data analytics experience in artificial intelligence and data architectures.
  • Nikos’s work could take Bio-Courier technology to the next level and future-proof SiSaf’s IP.”
    Nikos Tzagkarakis, Chief A.I.

GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification

Retrieved on: 
Tuesday, June 20, 2023
DNA, Plasmid, Genetic engineering, Workflow, Quatro, Biotechnology, GenScript Biotech, Research, Transfection, Laboratory, Risk, Bacteria, Cell engineering, Vaccine

PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up. The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid. Since its introduction, AmMag Quatro has been used at the forefront of biotech research, including breakthrough projects such as viral vector development for cell engineering and gene therapy.

Key Points: 
  • PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up.
  • The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid.
  • However, traditional plasmid purification methods are highly labor-intensive, inefficient, and prone to costly human or process errors.
  • It has exceeded our expectations in terms of time and cost savings, and it has become the standard for our organization's plasmid purification needs."

Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy

Retrieved on: 
Monday, June 12, 2023
Medical Devices, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, DNA, Drug development, Therapy, World Cancer Research Fund UK, Cognate, Cancer, Bladder cancer, Transfection, Food and Drug Administration Amendments Act of 2007, CDMO, Investigational New Drug, Patient, RNA interference, CRL, FDA, IND, NYSE, Food, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin , a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin , a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production.
  • The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
  • Curigin develops anticancer gene therapy products that utilize innovative genetically engineered viruses and novel RNAi technology to quickly and accurately block key disease-specific genetic signal pathways, effectively switching off genes responsible for tumor growth.
  • Expanding its comprehensive cell and gene therapy portfolio to span viral vector, plasmid DNA, and cell therapy production, through the acquisitions of Vigene Biosciences, Cobra Biologics, and Cognate BioServices in 2021, Charles River offers end-to-end support and supply chain simplification for gene therapy developers.

Oxford Biomedica Solutions Publishes Peer-Reviewed Journal Article On Novel Dual-Plasmid System, Resulting In Significantly Increased AAV Vector Productivity And Percentage Of Full Capsids Packaged

Retrieved on: 
Thursday, June 8, 2023
DS, Patient, Transfection, AAV, Full, Vaccine

The scientific team uses an innovative approach to develop and produce Adeno-Associated Virus (AAV) vectors used in the treatment of patients.

Key Points: 
  • The scientific team uses an innovative approach to develop and produce Adeno-Associated Virus (AAV) vectors used in the treatment of patients.
  • As part of our focus on innovation, a novel, dual-plasmid system has been developed for use in the transfection step of the manufacturing process.
  • This has resulted in significantly increased AAV vector productivity and percentage of full capsids packaged over traditional triple-plasmid transfection.
  • The peer-reviewed journal article was accepted on May 8th in Molecular Therapy – Methods and Clinical Development.

BioCentriq® and Kytopen® Expand Partnership to Expedite Impact of Transformative Gene-Editing Technology on Cell Therapy Manufacturing

Retrieved on: 
Tuesday, June 6, 2023
Massachusetts Institute of Technology, Partnership, CDMO, Therapy, Cell, Research, Patient, Transfection, MIT, Pharmaceutical industry, Vaccine

Partnerships allow us to validate the use of novel tools and technologies and introduce them to therapeutic developers.

Key Points: 
  • Partnerships allow us to validate the use of novel tools and technologies and introduce them to therapeutic developers.
  • At the conclusion of the evaluation, BioCentriq published promising results in a white paper entitled Efficient, Large-Scale Transfection of T-Cells Using Flowfect® Technology .
  • The extension of the partnership with BioCentriq will expand therapeutic developers' access to a leading non-viral cell engineering method by combining BioCentriq's process development expertise with Kytopen's Flowfect Discover™ platform.
  • This establishes BioCentriq as a preferred development and manufacturing partner for developers looking to utilize Kytopen's Flowfect® technology for rapid and automated optimization prior to scale-up.

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Abstract, Male, Bevacizumab, Progression-free survival, Platelet, DCR, Overalls, Survival, RECIST, OS, Trae tha Truth, Multimedia, Poster session, Transfection, Immunotherapy, Carboplatin, Antibody, PFS, ASCO, American Society of Clinical Oncology, Proteinuria, ORR, Incidence, Etoposide, ECOG, HCC, PD-1, Smoking, III, Society, SD, Vaccine, Pharmaceutical industry, Part, Safety, Pharmacokinetics, Patient

JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.

Key Points: 
  • JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.
  • Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session.
  • Two of the posters focus on the latest clinical research progress of Qilu Pharmaceutical's QL1706 in extensive-stage small cell lung cancer (ES-SCLC) and advanced hepatocellular carcinoma (HCC).
  • These findings support further investigation of QL1706 plus bevacizumab for first-line treatment of advanced HCC in a phase III clinical trial.

From Seattle to Space: Science that Began at the Allen Institute Blasts off to International Space Station

Retrieved on: 
Thursday, May 18, 2023
Immortalised cell line, DNA, Partnership, Cancer Institute, Scientific research on the International Space Station, Axiom Space, Cell, Cell proliferation, Biomedical Research, Research, Disease, Biomedical sciences, Transfection, Allen Institute for Cell Science, Allen Institute, Cell potency, NASA, Collection, Micro-g environment, Organelle, B cell, Health, Vaccine, Medical imaging, Cedars-Sinai Medical Center

SEATTLE, May 18, 2023 /PRNewswire/ --This Sunday (May 21) at 2:37 p.m. PDT1, astronauts from Axiom Space in partnership with Cedars-Sinai will blast off to the International Space Station carrying cells from the Allen Institute for Cell Science, a division of the Allen Institute. There, Axiom Space astronauts will perform experiments and send real-time data back to researchers at Cedars-Sinai as part of their study on the effects of microgravity on human cells.

Key Points: 
  • For the first time astronauts will transport Allen Institute cells into space where Cedars-Sinai researchers will study the effects of microgravity.
  • SEATTLE, May 18, 2023 /PRNewswire/ --This Sunday (May 21) at 2:37 p.m. PDT1, astronauts from Axiom Space in partnership with Cedars-Sinai will blast off to the International Space Station carrying cells from the Allen Institute for Cell Science , a division of the Allen Institute.
  • The experiments are part of the Ax-2 mission , funded by NASA and Axiom Space, and represent a major milestone: It will be the first time Allen Institute-generated cells are flown to space.
  • These cells are part of the publicly available Allen Cell Collection , a suite of human induced pluripotent stem cells gene-edited to illuminate different parts of the cell.

Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the Advancement of Stem Cell-Based Therapies

Retrieved on: 
Tuesday, May 16, 2023
ISS National Lab, Axiom Space, DNA, Therapy, SPACE, Stroke, ISS, Cancer, International Space Station, Brain, Research, Cell, Fibroblast, Transfection, United States national laboratories, EDT, Science, Kennedy Space Center, Regenerative medicine, Dementia, NASA, Patient, Commerce, B cell, Scientific research on the International Space Station, Health, Environment, Gene, Axiom Mission 2, Cedars-Sinai Medical Center, Veterinary medicine, Mobile phone, Pharmaceutical industry

Stem cell-based therapies are one possible solution; however, these types of treatments require large numbers of stem cells that are not easy to produce.

Key Points: 
  • Stem cell-based therapies are one possible solution; however, these types of treatments require large numbers of stem cells that are not easy to produce.
  • Scientists are working to understand how to grow large amounts of high-quality adult stem cells for cell therapy.
  • For this investigation, the team will send both stem cells and skin cells to the space station for a period of five days.
  • The skin cells will be used to study microgravity's effects on the early stages of transfection—the process of reprogramming adult cells into stem cells.

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Inflammation, Temperature, GH, Cryogenic electron microscopy, Endocrine gland, Risk, Cell, ALS, Virus, Gene, DSM-IV codes, Research, Gene expression, Ion, AUC, American Society of Gene and Cell Therapy, Liver, Neoplasm, AAV2, Kinetics, Death, Poster, HPLC, Genome, Safety, Neuron, Growth hormone, Muscular dystrophy, STR, Transfection, AAV, Hepatocyte, CAR, Sequence, Animal, CMV, Immune system, Cancer, AEX, Plasmid, PH, Neurological disorder, Human, NF-κB, Riboswitch, LDH, DSW, RNA, Skeletal muscle, CAG, Sure, Annual general meeting, Mouse, Society, FTD, Vaccine, Publication

RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.

Key Points: 
  • RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.
  • We demonstrate that with a bioavailable small molecule inducer, CAR-T activity can be precisely tuned and “remotely” controlled in vivo.
  • However, excessive amounts of transgene from unregulated vectors may limit the breadth of applicability of gene therapy.
  • Collectively, these results show we have established a robust platform to screen engineered promoters for applications to skeletal muscle gene therapies.

FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis

Retrieved on: 
Monday, May 15, 2023
Bone, Osteopetrosis, Therapy, Paratriathlon, RNA, Transfection, Small RNA, Pain, CLCN7, Hydrolysis, Patient, Anomaly, Orphan, Silicon, Birth, Osteoclast, FDA, Particle size, Scoliosis, ADO, Pharmaceutical industry, Vaccine

In addition, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.

Key Points: 
  • In addition, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.
  • FDA Orphan Drug Designation provides SiSaf with incentives such as tax credits for clinical trials, exemption from user fees, and expanded marketplace exclusivity.
  • The Rare Pediatric Disease Designation entitles SiSaf to apply for a priority review voucher that can be used to have the drug approval process expedited by the FDA.
  • SiSaf’s Founder and CEO, Dr. Suzanne Saffie-Siebert, said, “Being granted Orphan Drug Designation and Rare Pediatric Disease Designation is a major milestone in our drive to move our revolutionary siRNA treatment forward to alleviate the pain and suffering that Osteopetrosis ADO2 inflicts.